Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RESEARCH TOOLSreports
Holding RXRX?
Track your performance easily
RXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.89 - $15.74
Previous Close$6.18
Volume10.54M
Average Volume (3M)5.03M
Market Cap
$1.77B
Enterprise Value$1.43B
Total Cash (Recent Filing)$427.65M
Total Debt (Recent Filing)$90.63M
Price to Earnings (P/E)―
Beta3.30
Next Earnings
Mar 04, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding286,640,833
10 Day Avg. Volume7,412,396
30 Day Avg. Volume5,028,400
Standard Deviation0.28
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.37
Price to Sales (P/S)30.66
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.07
Enterprise Value/Gross Profit1.11K
Enterprise Value/Ebitda-5.48
Forecast
1Y Price Target
$10.17Price Target Upside64.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Recursion Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentRecursion achieved a milestone by rapidly progressing from target identification to IND approval for REC-1245 in just 18 months, showcasing its efficiency and potential in drug development.
Financial StrengthRecursion concluded the third quarter with a strong cash position of $427.6 million, providing a solid foundation for future growth and innovation.
Strategic PartnershipsRecursion's planned merger with Exscientia is anticipated to close ahead of schedule, bringing new pharma partnerships with BMS, Sanofi, and Merck KGaA, and enhancing its precision oncology assets.
Bears Say
Clinical Trial ResultsTopline results suggest only a nominal reduction in the size of lesions at the highest dose (400 mg) vs. placebo.
Deal Execution RiskAggressive headcount rationalization is implied by these synergies, adding an element of deal execution risk.
Financial PerformanceSG&A expenses were above consensus expectations.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $5.88 and its highest was $15.74 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Currently, no data Available
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 107 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.333 by -$0.007.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -$0.42.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 279,602,260 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.333. Following the earnings report the stock price went down -0.574%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Among the largest hedge funds holding Recursion Pharmaceuticals’s share is ARK Investment Management LLC. It holds Recursion Pharmaceuticals’s shares valued at 211M.
---
Recursion Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.17 (64.70% Upside)
$10.17 (64.70% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 19.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.99%
12-Months-Change
Fundamentals
Return on Equity
-78.49%
Trailing 12-Months
Asset Growth
15.17%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
---
RXRX Company Deck
---
RXRX Earnings Call
Q2 2024
0:00 / 0:00
---
RXRX Stock 12 Month Forecast
Average Price Target
$10.17
▲(64.70% Upside)
Technical Analysis
Best Analysts Covering RXRX
1 Year
---